China is increasingly positioning itself as a destination for international medical tourism by leveraging lower costs for advanced procedures, such as CAR-T cell therapy, and expanding access to innovative medical technologies. While traditional regional hubs like Thailand and South Korea have long dominated the market for cosmetic and elective surgeries, China is attempting to shift its focus toward high-value, complex clinical treatments. The industry remains in its early stages, with specialized zones like Hainan’s Lecheng International Medical Tourism Pilot Zone serving as the primary gateway for foreign patients seeking therapies not yet widely available in the mainland.
The global medical tourism market is projected to reach $126 billion by 2035, up from an estimated $34 billion today, according to data from Grand View Research. Within this expanding sector, China’s own medical tourism economy is expected to grow from $1.3 billion in 2025 to $3.4 billion by 2035, according to projections from Market Research Future. This growth is supported by a strategic pivot in the Chinese economy, which aims to transition from a manufacturing-heavy model toward a provider of high-end, specialized services.
The Economics of Advanced Oncology in China
One of the most significant drivers for international interest in Chinese healthcare is the availability and cost-effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy. This complex oncology treatment involves extracting a patient’s T cells, genetically modifying them in a laboratory to recognize and attack specific cancer proteins, and re-infusing them into the patient. According to the American Cancer Society, a single infusion of CAR-T therapy in the United States can cost between $300,000 and $475,000. In China, the same procedure currently ranges from approximately $150,000 to $180,000.
The price gap could widen further as Chinese regulators continue to approve new therapies. The National Medical Products Administration (NMPA) has recently accepted marketing applications for therapies that aim to bring costs below 300,000 yuan, or roughly $44,000, significantly undercutting Western pricing models. These costs reflect both the lower domestic overhead and a deliberate effort to scale production of cutting-edge biotechnologies.
Hainan as a Specialized Medical Gateway
At the center of China’s strategy is the Lecheng International Medical Tourism Pilot Zone, located in the Hainan Free Trade Port. Established in 2013, the zone functions as a regulatory sandbox where foreign medical devices and drugs that have not yet received full approval for use in the rest of mainland China can be utilized under controlled conditions. This policy allows international patients to access global medical innovations that are often subject to lengthy regulatory delays in other jurisdictions.
Despite the zone’s advanced capabilities, the volume of international patients remains modest. Last year, the pilot zone recorded a few thousand foreign medical tourists, a figure that pales in comparison to the hundreds of thousands of domestic patients who traveled to the region for care. The disparity highlights the current “infancy” of the sector as it works to build international trust and infrastructure.
Strategic Integration and Global Competition
The shift toward medical tourism is not merely a commercial endeavor but part of a broader goal to integrate the Chinese healthcare system with international standards. Jeroen Groenewegen-Lau, an analyst at the Mercator Institute for China Studies, notes that many advanced treatments developed in China have outpaced the domestic healthcare system’s ability to pay for them, creating an incentive for the country to attract foreign patients who can help sustain the development of these high-tech sectors.
For patients, the choice often comes down to a simple calculation of access and cost. As Victor Cao, operations director of Joyful Medical in Shanghai, observes, the paradigm has shifted. Where Chinese patients once looked abroad for treatments unavailable at home, the domestic availability of advanced procedures is now drawing international attention. This transition is being amplified by broader visa-free policies, which have made it easier for international travelers to visit the country for both tourism and medical consultations.
Industry observers expect the next phase of this development to be defined by how effectively China can standardize the quality of care and maintain the regulatory integrity of its specialized medical zones. As of now, there are no specific dates for the next major policy updates regarding the expansion of the Lecheng pilot model to other provinces. Interested parties and prospective patients are encouraged to monitor updates from the Hainan Free Trade Port administration for official announcements regarding new medical service inclusions and visa requirements.
We welcome your thoughts on the evolution of global medical tourism. Please share your experiences or questions in the comments section below.
Keep reading